PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.16%
Negative net income growth while AGEN stands at 26.94%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
8.11%
Some D&A expansion while AGEN is negative at -0.65%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
14.88%
Lower deferred tax growth vs. AGEN's 1214.29%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
33.33%
SBC growth well above AGEN's 0.77%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-359.86%
Both reduce yoy usage, with AGEN at -56.07%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.03%
Both reduce yoy usage, with AGEN at -93.28%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-14.88%
Both negative yoy, with AGEN at -152.17%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-25.31%
Both yoy CFO lines are negative, with AGEN at -12.53%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-2962.50%
Negative yoy CapEx while AGEN is 4.14%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2962.50%
We reduce yoy invests while AGEN stands at 4.47%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
56.30%
We repay more while AGEN is negative at -1.51%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
23135.79%
We slightly raise equity while AGEN is negative at -62.37%. John Neff sees competitor possibly preserving share count or buying back shares.
100.00%
Buyback growth of 100.00% while AGEN is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.
